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Abstract
Background
Controlled hypoventilation while accepting hypercapnia has been advocated to reduce
ventilator-induced lung injury. The aim of the study was to analyze outcomes of a cohort of
immunocompromised children with acute respiratory distress syndrome (ARDS) ventilated
with a strategy of stepwise increasing PCO2 targets up to 140 mm Hg.
Methods
Retrospective analysis of outcomes of a cohort of children with oncologic disease or after
stem cell transplantation and severe respiratory failure in comparison with a historical con-
trol cohort.
Results
Out of 150 episodes of admission to the PICU 88 children underwent invasive mechanical
ventilation for >24h (overall survival 75%). In a subgroup of 38 children with high ventilator
requirements the PCO2 target ranges were increased stepwise. Fifteen children survived
and were discharged from the PICU. Severe pulmonary hypertension was seen in two
patients and no case of cerebral edema was observed. Long term outcome was available
in 15 patients and 10 of these patients survived without adverse neurological sequelae.
With introduction of this strategy survival of immunocompromised children undergoing
mechanical ventilation for >24h increased to 48% compared to 32% prior to introduction
(historical cohort).
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Conclusions
A ventilation strategy incorporating very high carbon dioxide levels to allow for low tidal vol-
umes and limited inspiratory pressures is feasible in children. Even severe hypercapnia may
be well tolerated. No severe side effects associated with hypercapnia were observed. This
strategy could potentially increase survival in immunocompromised children with severe
ARDS.
Introduction
Permissive hypercapnia is a ventilation strategy to allow for an unphysiologically high partial
pressure of carbon dioxide (PCO2) to permit lung protective ventilation with low tidal vol-
umes. Current guidelines recommend the concept of low tidal volume ventilation and permis-
sive hypercapnia for patients with sepsis, acute respiratory distress syndrome (ARDS) or acute
on chronic respiratory failure [1;2]. However, there is insufficient clinical data which levels of
PCO2 can safely be allowed for, and there are no data available if such a strategy translates into
a survival benefit.
In several models hypercapnic acidosis was associated with benefits on lung and distant
organs apart from the reduction of ventilation parameters: In in vivo and ex vivo models for
ventilator induced lung injury [3–5], ARDS [6;7], ischemia reperfusion injury [8;9] and sepsis
[10] therapeutic hypercapnia through inspired carbon dioxide attenuated lung injury, as mea-
sured by gas exchange, reduced cytokine release, lung edema formation and histological lung
injury. Differential effects of hypercapnia on bacterial infection i.e. pneumonia have been
observed [11]: While hypercapnia can prevent lung damage in established and treated pneu-
monia, increased bacterial loads and deteriorating lung function was observed in evolving
untreated pneumonia [12;13]. The clinical impact of potential negative effects of hypercapnic
acidosis like impaired wound healing [14;15] or decreased fluid resorption from the lung [16]
is unclear. Nevertheless, all these effects may add on to a possible benefit of a low pressure, low
tidal volume strategy in regard to lung protection.
Very few clinical trials have addressed permissive hypercapnia until present: In the late 90s
Amato et al. compared in a randomized controlled trial a lung protective strategy including
low tidal volumes and permissive hypercapnia with standard therapy [17]. They observed a
reduction in mortality; however effects of low tidal volumes and hypercapnia were not differ-
entiated. In 2000 the ARDS Network trial demonstrated superiority of a low tidal volume
strategy on mortality [18]. A secondary analysis of this trial showed lung protective properties
of mild hypercapnic acidosis in the subgroup of injuriously ventilated patients [19]. Very
recently, in contrast, the concept of permissive hypercapnia was challenged by results from a
large prospective observational database. In adults with ARDS an increased mortality was asso-
ciated with the presence of hypercapnia, even after correction for the more severe ARDS in
these patients [20].
Stimulated by experimental and clinical data in 2003 we began to use permissive hypercap-
nia in children with primary immunodeficiency, with oncologic disease and patients after
human stem cell transplantation (HSCT) if mechanical ventilation otherwise would have been
regarded as too injurious and because we considered extracorporal membrane oxygenation
(ECMO) in such patients futile.
Permissive hypercapnia for ARDS
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Abbreviations: ARDS, acute respiratory distress
syndrome; HSCT, human stem cell transplantation;
PCO2, partial pressure of carbon dioxide; PICU,
pediatric intensive care unit; PIP, peak inspiratory
pressure.
The aim of this study is to report outcomes, experiences, and the side effects in this unique
patient cohort treated with a protocol of stepwise allowing for very high PCO2 values, and to
compare those results with a historical cohort from our unit.
Materials and methods
This retrospective cohort study was approved by the ethics committee of the University of
Ulm, Germany (No. 230/11).
All admissions of immunocompromised patients to the level three pediatric intensive care
unit, Department for Pediatrics and Adolescent Medicine, Ulm University between 1996
and 2010 were identified by review of admission logs of the Pediatric Intensive Care Unit
(PICU). Immunocompromised patients were defined as primary immunodeficiency, ongoing
chemotherapy for malignancy or ongoing treatment with allogenic HSCT. Medical records of
included patients were reviewed.
First, patients invasively ventilated with target arterial PCO2>60 mm Hg for >24h were
identified from the entire cohort. In case of repeated readmissions to the PICU including inva-
sive ventilation only the last (sometimes fatal) episode was included.
In November 2003 the concept of permissive hypercapnia was introduced in an individual
patient based on experimental data as an individual treatment attempt with success and, on
from that time point, it was applied to all following patients with respiratory failure and high
ventilator settings to maintain a tidal volume of<6 ml/kg and a peak inspiratory pressure
(PIP) of<30 mbar, if possible. In general hypercapnia was permitted early after intubation
with a lower range (i.e. 50–70 mm Hg) and subsequently increased by 10–20 mm Hg/per day
up to ranges of max. 120–140 mm Hg if necessary. Other unit policies to protect the lung
included noninvasive ventilation for less severe respiratory distress, higher ventilation rates
during invasive ventilation adjusted to individual lung mechanical properties, avoidance of air
trapping and high frequency oscillatory ventilation as rescue strategy. These strategies had
been introduced many years before introduction of the concept of permissive hypercapnia.
Patient charts were analyzed in detail: All available information on patient history, clinical
course, ventilation parameters, laboratory values, X-ray images, echocardiography as well as
outcome parameters were collected. The PRISM24 III score was determined at the day of intu-
bation according to [21]. The PELOD score was determined throughout stay in the PICU
according to [22]. Long term outcome was taken from the medical records of the last follow up
visit.
For comparison of outcome variables, a historical cohort from the 7 years before (1/1996-
10/2003) was compared to the Permissive Hypercapnia cohort (11/2003-12/2010). All episodes
of admissions of immunocompromised children were identified between 1/1996 and 12/2010.
Patient data of interest were identified from medical records and are given below. From both
cohorts a subcohort was defined, which included immunocompromised patients with invasive
ventilation for>24h. Again, if patients were repeatedly admitted and underwent mechanical
ventilation more than once, only the last episode of admission (expected to be associated with
the highest risk for death) was included.
Statistics: Data were processed in Excel (Microsoft, Redmond, WA). Data were analyzed
using SigmaStat V2.03 (Systat Software, San Jose, California) or SAS V9.2 (SAS Institute,Cary,
N.C.). Data are reported as median and interquartile ranges or numbers and percent. Statisti-
cal analysis of numerical or categorical data was performed using a t-test, u-test, Χ2-test or
fishers exact test as appropriate. Comparison of groups with repeated measurements were ana-
lyzed by using a mixed model (SAS). Survival analysis was done using the the LogRank test.
Permissive hypercapnia for ARDS
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Results
Thirty eight immunocompromised patients undergoing mechanical ventilation with moderate
to high PCO2 target ranges (>60 mm Hg) were identified. Patient data are given in Table 1.
ARDS was moderate in 3 patients and severe in all others [23]. Survivors had a lower
PRISM24 III at time of intubation and lower PELOD scores during the stay. There was no
difference in ventilation settings and parameters of gas exchange at the time of intubation
between surviving and non-surviving patients.
Course of PCO2 is given in Fig 1A for surviving and non-surviving patients of the cohort
ventilated at high PCO2 targets. The highest individual PCO2 target range aimed for by the
clinical team was 120 to 140 mm Hg. Cumulative PCO2 values measured in the entire cohort
over time is given in Fig 1F. By unit policy the target range for PCO2 was gradually increased
by 10–20 mm Hg per day (Fig 1A). We observed a rapid metabolic compensation for respira-
tory acidosis, therefore, pH remained within acceptable limits despite very high PCO2 levels in
the majority of patients (Fig 1B and 1C). However, there was a high variability in PCO2 levels
(Fig 1B and 1C). PIP was targeted to remain below 30 cm H2O (Fig 1D). Initial ventilator rate
was 35 (30;47)/min (median (interquartile range)) 2-4h after intubation.
Overall 15 out of 38 patients survived (39%; Fig 2A). Length of invasive ventilation was 13
(9; 29) days for the survivors and 9 (6;21) days for the non-surviving patients (Fig 2B). Notably,
one patient was successfully extubated after 52 days of invasive ventilation.
We observed pneumothoraces in 6/38 patients and pneumomediastinum in 4/38 patients.
Pulmonary hypertension was observed in 7/38 patients and was graded severe in two patients.
Occurrence of pulmonary hypertension was always associated with death. Abnormal cardiac
Table 1. Patient data (Permissive hypercapnia cohort).
All
n = 38
Survivors
n = 15
Non-survivors
n = 23
p
Age (years) 3.83(0.57;9.2) 3.52 (0.59;8.44) 3.89 (0.59;8.49) 0.88
Weight (kg) 12.6 (7.1;20.9) 12.6(7.4;25.9) 12.7(6.54;20.7) 0.77
Gender (f/m) 12/26 4/11 8/15 0.47
Underlying disease
Immunodeficiency n = 16(42) n = 7(47) n = 9(39) 0.9
Leukemia n = 10(26) n = 4(27) n = 6(26) 1.0
Solid tumor n = 2(5) n = 1(7) n = 1(4) 1.0
Other n = 10(26) n = 3(20) n = 7(30) 0.7
Stem cell transplantation 23(61) 11(73) 12(52) 0.33
HLA identical 10 6 4
HLA haploidentical 13 5 8
Scores
PRISM 24* 16(10;24) 12(5;16) 20(12;27) 0.001
Pelod-Score 43(32;52) 32(23;42) 44(34;53) 0.004
Intubation
paO2/FiO2 (mm Hg) 84(64;110) 81(64;124) 84(62;110) 0.73
PIP (cm H2O) 29(24;33) 32(24;36) 28(24;33) 0.68
PEEP(cm H2O) 10(8;12) 10(8;12) 9(7;12) 0.23
FiO2 0.78(0.6;1.0) 0,7(0.6;0.85) 1.0(0.6;1.0) 0.17
*day of intubation, median (1.;3. quartile)
https://doi.org/10.1371/journal.pone.0179974.t001
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contractility was seen in nine patients. It was severe in two patients. Patients that developed
renal failure had a significantly lower survival than patients without renal failure (Table 2).
Long term outcome of surviving patients is given in Table 3. There were further 6 late
deaths not associated with the episode of respiratory failure. Neurological outcome of the sur-
vivors after treatment with severe permissive hypercapnia was normal in 10 survivors. Mild
learning difficulties were found in two patients and three patients had moderate or severe
mental impairment (Table 3). Neurologic impairment was present in two of them prior to
admission or might be related to an large underlying brain tumor in one patient.
To estimate the impact of this strategy of allowing for extreme hypercapnia on patient sur-
vival we compared this cohort to a seven year historical cohort prior to introduction of the
permissive hypercapnia concept. Data of the two cohorts are given in Tables 4 and 5. Despite
Fig 1. Blood gas result, ventilation parameters, and number of blood gases of the cohort of
immunocompromised children (n = 38) ventilated with allowance of severe hypercapnia. Dashed
line = survivors; solid line = non-survivors. Median and interquartile ranges are given.
https://doi.org/10.1371/journal.pone.0179974.g001
Permissive hypercapnia for ARDS
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Fig 2. Survival and length of ventilation of a cohort of immunocompromised 38 children exposed to
severe permissive hypercapnia. (A) Survival plot and (B) length of ventilation. Dashed line = survivors; solid
line = non-survivors.
https://doi.org/10.1371/journal.pone.0179974.g002
Permissive hypercapnia for ARDS
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the tendency towards more severe respiratory failure (as assessed by the PaO2/FiO2 gradient),
chance of survival was significantly higher in the permissive hypercapnia cohort looking at all
episodes of admissions of immunocompromised patients to the PICU (Fig 3A) as well as look-
ing at children ventilated24h (Fig 3B).
Table 2. Adverse events (Permissive hypercapnia cohort).
All
n = 38
Survivors
n = 15
Non-survivors
n = 23
p
Pneumothorax n = 6 n = 1 n = 5 0.37
Mediastinal emphysema n = 4 n = 2 n = 1 0.55
Pulm. hypertension n = 7 - n = 7 0.029
mild n = 3 - n = 3
medium n = 2 - n = 2
severe n = 2 - n = 2
Abnormal cardiac function n = 9 n = 2 n = 7 0.27
mild n = 4 n = 1 n = 3
medium n = 3 n = 1 n = 2
severe n = 2 - n = 2
Nosocomial sepsis n = 10 n = 3 n = 7 0.71
Ventilator-associated pneumonia n = 2 - n = 2 0.51
Renal failure n = 19 n = 4 n = 15 0.046
Other adverse events n = 1 seizure n = 1 seizure 1.0
n = 1 pulm. hemorrhage
https://doi.org/10.1371/journal.pone.0179974.t002
Table 3. Long term outcome (Permissive hypercapnia cohort).
Pat. Neurological outcome Pulmonary outcome other alive Cause of death
(time to death in
days)
1 Mild learning difficulties Restrictive pulmonary disease y n.a.
4 Mild learning difficulties Lung fibrosis 24h- O2
dependence
CMV-reactivation/immunosuppression n Lung fibrosis (95)
5 Normal None Erythrodermia, paresthesias Abn. liver function tests
thrombocytopenia
n Sepsis/pneumonia
(412)
6 Moderate learning
difficulties
Normal Hypogonadism, herpes zoster y n.a.
8 Normal Normal n Sepsis, DNR (6)
10 Normal Normal Craniosynostosis y n.a.
12 Normal Normal n Sepsis (210)
19 Normal Normal Mitral valve insufficieny y n.a.
21 Moderate learning
difficulties
Chronic lung disease, 24h O2
dependence
Chron GVHD of liver and skin, seizures, art
Hypertension, EBV-Lymphoma
n EBV (1229)
22 Normal Mild obstructive pulmonary
disease
Hemiparesis, Dermal mycosis, intracranial calcification,
short stature
y n.a.
24 Normal Moderate obstructive pulmonary
disease
Dermatitis, seizures y n.a.
27 Normal y n.a.
30 Normal Microcephaly, normal IQ, specific language impairment y n.a.
34 Mental impairment Recurrent pneumonias Gastroesophageal reflux n Progress of brain
tumor (43)
38 Normal Normal y n.a.
https://doi.org/10.1371/journal.pone.0179974.t003
Permissive hypercapnia for ARDS
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Discussion
Herein, we report the single center treatment results of immunocompromised children with
severe ARDS treated according to a protocol of stepwise increase of PCO2 to allow for lung
protective ventilation with low tidal volumes and limited inspiratory pressures. Our findings
indicate that: first the feasibility of such a strategy, second the limited rate of severe side-effects
like pulmonary hypertension or neurological complications, third we provide some long term
outcome data and, furthermore, there is some evidence that such a strategy might result in
higher survival rates.
Respiratory failure during severe immunosuppression i.e. oncologic disease and after
HSCT remains a major threat. More recent reports indicate improved PICU survival rates of
Table 4. Comparison of the recent permissive hypercapnia period with a historical period. All admissions of immunocompromised patients to the
PICU.
Cohort A
3.2003–12.2010
Cohort B
1.1996–2.2003
p
Admissions (n) 150 121
Patients (n) 101 101
Any invasive ventilation;n (%) 88 (59) 60 (50) 0.26
Age (y) 5.1(1.3;12.5) 4.0(1;12.5) 0.41
Gender (male) 100(71) 76(60) 0.59
Length of PICU stay (d) 3(1;12) 5(1;12) 0.23
Survival (%) 113 (75) 71(59) 0.005
https://doi.org/10.1371/journal.pone.0179974.t004
Table 5. Comparison of the recent permissive hypercapnia period with a historical period. Patients ventilated24h*.
Cohort A
3.2003–12.2010
Cohort B
1.1996–2.2003
p
Patients (n) 58 47
Age (y) 3.8(0.7;8.8) 2.7(0.5;12.2) 0.88
Gender (male) 41(71) 28(60) 0.26
Type of disease
Immunodeficiency 24(41) 20(43) 0.93
Leukemia 13(22) 12(26) 0.89
Solid tumor 7(12) 2(4) 0.28
Other 14 (24) 13(28) 0.85
HSCT (%) 32 (55) 33(70) 0.17
PRISM III score 17(9;21) 16(11;20) 0.93
paO2/FiO2 (mm Hg) 104(67;160) 122(100;166) 0.057
pH 7.35(7.26;7.43) 7.4(7.3;7.44) 0.25
PIP (mbar) 30(24;34) 26(24;33) 0.52
PEEP (mbar) 9(6;11) 8(5;10) 0.02
Ventilator rate (/min) 35(27;44) 35(25;45) 0.94
Permissive hypercapnia (n) 38(66) -(-)
Length of PICU-stay (d) 13.5(4.3;24) 9(3.5;16) 0.12
Survival (%) 28 (48) 15(32) 0.135
*In case of repeated episodes only the last episode per patient is included HSCT human stem cell transplantation, PIP positive inspiratory pressure, PEEP
positive end-expiratory pressure
https://doi.org/10.1371/journal.pone.0179974.t005
Permissive hypercapnia for ARDS
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Fig 3. Comparison of the permissive hypercapnia period (Cohort A) with a historical period (Cohort
B). (A) Survival plots of all episodes of admission of immunocompromised children to the PICU. (B) Survival
plots of immunocompromised children ventilated >24h. Solid line = Permissive hypercapnia cohort; dashed
line = historical cohort.
https://doi.org/10.1371/journal.pone.0179974.g003
Permissive hypercapnia for ARDS
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59% (6 month survival of 43%) [24]; 58% [25]; and 58% [26] of admissions of children with
HSCT or oncologic disease requiring any mechanical ventilation. At a first glance, these results
seem to match well with our results, however, given the high proportion of HSCT patients in
our cohort, the exclusion of patients ventilated <24h and including only the last episode of
ventilation if patients were readmitted repeatedly, our results appear even more favorable.
For example, survival through their last PICU discharge decreased to 39% in the study from
Cincinnati for HSCT patients who needed any mechanical ventilation [26]. Another recent
study from Seattle differentiated HSCT patients ventilated for >24h and survival was as low as
25% in this subcohort [27]. Therefore, a survival rate of almost 40% appears to be rather high,
which might support our use of hypercapnia.
Various direct effects of hypercapnic acidosis have been described: these include attenua-
tion of inflammatory mediators i.e. attenuation of neutrophil function, antioxidative proper-
ties, reduction in proinflammatory cytokine levels and apoptosis. These effects have translated
into benefits in various preclinical models like ischemia-reperfusion or ventilation induced
lung injury [3;4;8;9]. Differential or negative effects were noted in sepsis/pneumonia and
organ recovery models [13;15]. As buffering reverses some of the effects [28] it is not clear if
these direct effects of acidosis become meaningful in our patients: We observed rapid meta-
bolic compensation in our cohort of patients eliminating severe acidosis quickly. Nevertheless,
our goal was to allow for a strategy of applying tidal volumes as low as possible at rather high
ventilator rates depending on the lung mechanical properties. This goal was achieved by
increasing the PCO2 target ranges daily to maximum levels. Recent experimental [7] and clini-
cal data [29;30] further support the use of ultraprotective low tidal volumes in the setting of
ARDS. However, in these publications progressive hypercapnia was avoided by extracorporal
CO2 elimination. This was disregarded in our patient subset because extracorporeal mem-
brane oxygenation is considered futile in hematologic disease [31].
Unwanted side effects have to be taken into account when using a strategy of allowing for
extreme hypercapnia. Early ARDS may be associated with acute cor pulmonale in adults in
about 20% of patients [32]. This may add to the pulmonary vasoconstriction caused by hyper-
capnia [33] and a PCO2>60 mm Hg was shown to be an independent risk factor for acute cor
pulmonale [32]. We observed pulmonary hypertension in a considerable number of patients,
however, it was regarded mild or moderate in the majority, as it was found by Cavalho et al.
[34]. Interestingly, despite increasing the risk for acute cor pulmonale an increased PCO2 was
not associated with death in the study of Lherithier et al. [32]. However, the presence of air-
leaks increased the risk for death 5-fold, suggesting that aiming for maximal lung protection
while carefully monitoring right heart cardiac function may finally sum up to the best benefit.
Abnormal cardiac function was seen in roughly a quarter of our patients. Despite some neg-
ative effects of hypercapnia on contractility we may expect an increase in cardiac output due to
an increase in sympatoadrenal activity [34]. Furthermore, tissue perfusion is directly increased
by hypercapnia and oxygen delivery into the tissues is enhanced by facilitated oxygen release
owing to a right shift of the oxygen binding curve [35;36]. Our patients frequently had been
treated with multiple cardiotoxic antineoplastic drugs prior to their episode of ARDS, there-
fore, it seems impossible to differentiate the impact of hypercapnia from a preexisting cardiac
disease, ARDS or infection with this retrospective study design.
Multiple reports of acute asthma reassure that even excessively high values of hypercapnia
can be survived without sequelae [37;38]. However, there are reports where acute exposure to
high CO2 was associated with cerebral vasodilation, and cerebral edema. Hypercapnia was
considered the main causative reason. In our study no patient suffered or died from clinically
relevant increased intracranial pressures.
Permissive hypercapnia for ARDS
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Some children treated with permissive hypercapnia suffered from learning disabilities or
even mental impairment long term. Neurologic sequelae after HSCT or severe ARDS in addi-
tion to underlying conditions are well recognized. Our data do not allow to determine the
exact cause of impairments among these possibilities, however, no episodes of severe hypoxia
or resuscitation were documented in these patients. The proportion of impaired survivors,
does not seem to be higher in our permissive hypercapnia cohort.
In the very recent prospective observational trial focusing on ARDS in adults the concept
of permissive hypercapnia was challenged, as presence of hypercapnia was associated with
increased mortality in this trial [20]. These findings remained significant even after correction
for the more severe lung disease in the subgroup of hypercapnia patients as evidenced by a
lower paO2/FiO2. In the hypercapnia cohort relevant higher ventilation settings (PIP/PEEP)
had been used compared to patients without hypercapnia and cardiovascular failure was
observed in 74% of these patients. This is in contrast to the observation in our cohort of chil-
dren where the risk for cardiovascular failure was much lower.
To unravel potential benefits from our ventilation strategy we compared the mortality
within 7 years after introduction of the permissive hypercapnia concept with the 7 preceding
years. However, patient data including a severity of illness score and parameters of gas
exchange showed a trend towards more severe lung disease in the latter cohort. Nevertheless,
survival in patients after introduction of the strategy of permissive hypercapnia ventilated
>24h increased by 16%. Obviously, we cannot be sure if this increased survival rate is due to
the ventilation policy only. Advances in survival rates in HSCT intensive care patients over
the years have also been observed by other centers [25;26]. However, a recent meta-regression
analysis challenges this impression for the subset of ventilated patients [39]. Furthermore, per-
missive hypercapnia is frequently incorporated in the new concepts of intensive care therapy,
therefore, may have contributed to some of the improvements seen by others [25;26]. Anyway,
there is considerable dispute about the best target ranges of PCO2 [40].
The increase in survival is modest. However, mechanical ventilation in ARDS in the setting
of immunosuppression is only a supportive measure to buy time for more causative therapies
to become effective. Therefore, optimizing ventilation may not alter outcomes if the underly-
ing cause of the ARDS cannot be sufficiently treated. In the survival curves, it seems that the
time window for such treatments has opened somewhat in our recent patient cohort even if
the final outcome was not altered tremendously. Multiple improvements in all aspects of care
will be necessary to achieve better results in respiratory failure after bone marrow transplanta-
tion or antineoplastic chemotherapy.
This study has multiple limitations: First, it is a retrospective study. Comparison with a his-
torical cohort bears numerous risks for bias, although we are not aware of major systematic
changes in regard to oncologic or antibiotic therapy between the episodes. Attending physi-
cians of oncology and intensive care did not change during study time. New guidelines for
intubation at lower thresholds were introduced at the very end of the second time period [41]
and have, therefore, not contributed to the results. Furthermore, hypercapnia was introduced
only, if the peak pressures exceeded 30 mm Hg and the daily increase in PCO2 targets was
roughly 10 mm Hg. However, this was modified depending on the patient and at the discretion
of the physician responsible. To minimize selection bias all patients admitted to the PICU dur-
ing the study period were analysed irrespective of exposure to hypercapnic ventilation. Patient
numbers are low in this study, however, even in large transplantation centers the number of
such cases is limited. Therefore, large scale randomized trials for this subset of patients will
remain challenging. Furthermore, there is a wide variety and complexity of underlying diseases
as well as reasons for respiratory failure. By pooling these data, potential beneficial effects
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might be blurred, as some individual patients might benefit more than others. Therefore,
results have to be interpreted cautiously.
Herein we report our experiences with the strategy of consequently increasing PCO2 targets
in order to limit lung damage from high ventilation pressures by allowing for very high PCO2.
This concept, so far, has to be regarded as individual treatment attempt in a subset of very sick
immunocompromised patients with anticipated high morbidity and high mortality. We think
a larger scale multi center randomized trial is urgently warranted to assess effects of such a
strategy on outcome and to define side effects.
Conclusion
A ventilation strategy incorporating very high permissive hypercapnia seems to be feasible
in immunocompromised children with severe respiratory failure secondary to ARDS. Even
high levels of PCO2 are tolerated well. No severe side effects associated with hypercapnia were
observed. This strategy potentially could increase survival in immunocompromised children
with severe ARDS.
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